Response to Comment on "Replacing the NCCN's Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice?".
- Published in:
- 2020
- By:
- Publication type:
- Letter
Works matching IS 11707690 AND DT 2020 AND VI 38 AND IP 8
Results: 13
1
2
Comment on "Replacing the NCCN's Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice?".
- Published in:
- 2020
- By:
- Publication type:
- Letter
3
Does Cost-Effectiveness Analysis Really Need to Abandon the Incremental Cost-Effectiveness Ratio to Embrace Net Benefit?
- Published in:
- 2020
- By:
- Publication type:
- Editorial
4
Correction to: A Systematic Review of Methodological Variation in Healthcare Provider Perspective Tuberculosis Costing Papers Conducted in Low- and Middle-Income Settings, Using An Intervention-Standardised Unit Cost Typology.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
5
Correction to: Real-World Evidence on the Patterns of Increased Societal Economic Relapse Costs in Patients with Multiple Sclerosis.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
6
A Systematic Review of Methodological Variation in Healthcare Provider Perspective Tuberculosis Costing Papers Conducted in Low- and Middle-Income Settings, Using An Intervention-Standardised Unit Cost Typology.
- Published in:
- PharmacoEconomics, 2020, v. 38, n. 8, p. 819, doi. 10.1007/s40273-020-00910-w
- By:
- Publication type:
- Article
7
Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis.
- Published in:
- PharmacoEconomics, 2020, v. 38, n. 8, p. 883, doi. 10.1007/s40273-020-00917-3
- By:
- Publication type:
- Article
8
Why it's Time to Abandon the ICER.
- Published in:
- 2020
- By:
- Publication type:
- Editorial
9
Calculating and Interpreting ICERs and Net Benefit.
- Published in:
- PharmacoEconomics, 2020, v. 38, n. 8, p. 785, doi. 10.1007/s40273-020-00914-6
- By:
- Publication type:
- Article
10
Valuing the AD-5D Dementia Utility Instrument: An Estimation of a General Population Tariff.
- Published in:
- PharmacoEconomics, 2020, v. 38, n. 8, p. 871, doi. 10.1007/s40273-020-00913-7
- By:
- Publication type:
- Article
11
Adherence to Discounting Guidelines: Evidence from Over 2000 Published Cost-Effectiveness Analyses.
- Published in:
- PharmacoEconomics, 2020, v. 38, n. 8, p. 809, doi. 10.1007/s40273-020-00916-4
- By:
- Publication type:
- Article
12
Estimating the Value of New Antimicrobials in the Context of Antimicrobial Resistance: Development and Application of a Dynamic Disease Transmission Model.
- Published in:
- PharmacoEconomics, 2020, v. 38, n. 8, p. 857, doi. 10.1007/s40273-020-00906-6
- By:
- Publication type:
- Article
13
Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States.
- Published in:
- PharmacoEconomics, 2020, v. 38, n. 8, p. 839, doi. 10.1007/s40273-020-00905-7
- By:
- Publication type:
- Article